VistaGen Therapeutics (VTGN) Competitors $4.05 0.00 (0.00%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$4.11 +0.06 (+1.36%) As of 10/17/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTGN vs. FULC, INBX, ATXS, CYRX, SLDB, ALMS, DRUG, LXEO, RAPT, and AUTLShould you be buying VistaGen Therapeutics stock or one of its competitors? The main competitors of VistaGen Therapeutics include Fulcrum Therapeutics (FULC), Inhibrx Biosciences (INBX), Astria Therapeutics (ATXS), CryoPort (CYRX), Solid Biosciences (SLDB), Alumis (ALMS), Bright Minds Biosciences (DRUG), Lexeo Therapeutics (LXEO), Rapt Therapeutics (RAPT), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. VistaGen Therapeutics vs. Its Competitors Fulcrum Therapeutics Inhibrx Biosciences Astria Therapeutics CryoPort Solid Biosciences Alumis Bright Minds Biosciences Lexeo Therapeutics Rapt Therapeutics Autolus Therapeutics VistaGen Therapeutics (NASDAQ:VTGN) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations. Do analysts rate VTGN or FULC? Fulcrum Therapeutics has a consensus price target of $9.60, suggesting a potential upside of 6.79%. Given Fulcrum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Fulcrum Therapeutics is more favorable than VistaGen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VistaGen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Fulcrum Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Do institutionals & insiders believe in VTGN or FULC? 78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better earnings and valuation, VTGN or FULC? Fulcrum Therapeutics has higher revenue and earnings than VistaGen Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVistaGen Therapeutics$490K253.58-$51.42M-$1.78-2.28Fulcrum Therapeutics$80M6.08-$9.73M-$1.22-7.37 Is VTGN or FULC more profitable? Fulcrum Therapeutics' return on equity of -31.05% beat VistaGen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VistaGen TherapeuticsN/A -74.06% -64.10% Fulcrum Therapeutics N/A -31.05%-28.96% Does the media prefer VTGN or FULC? In the previous week, Fulcrum Therapeutics had 6 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 7 mentions for Fulcrum Therapeutics and 1 mentions for VistaGen Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.31 beat VistaGen Therapeutics' score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VistaGen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, VTGN or FULC? VistaGen Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.93, indicating that its share price is 193% more volatile than the S&P 500. SummaryFulcrum Therapeutics beats VistaGen Therapeutics on 14 of the 16 factors compared between the two stocks. Get VistaGen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTGN vs. The Competition Export to ExcelMetricVistaGen TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$124.26M$3.40B$6.10B$10.49BDividend YieldN/A2.28%5.73%4.80%P/E Ratio-2.2823.1685.3827.13Price / Sales253.58269.13520.13179.96Price / CashN/A47.1837.2361.22Price / Book1.6610.4112.236.52Net Income-$51.42M-$52.77M$3.33B$276.93M7 Day Performance0.50%2.31%1.18%1.93%1 Month Performance33.22%11.13%6.16%2.19%1 Year Performance31.92%11.12%60.00%35.00% VistaGen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTGNVistaGen Therapeutics0.4898 of 5 stars$4.05flatN/A+32.4%$124.26M$490K-2.2840News CoverageFULCFulcrum Therapeutics1.3999 of 5 stars$8.75-2.7%$9.60+9.7%+153.2%$486.28M$80M-7.17100News CoverageINBXInhibrx Biosciences2.0332 of 5 stars$34.38+5.9%N/A+130.4%$470.27M$200K-3.25166ATXSAstria Therapeutics2.0855 of 5 stars$8.47+1.9%$29.50+248.3%+1.9%$468.97MN/A-4.2130Trending NewsAnalyst DowngradeCYRXCryoPort3.1705 of 5 stars$9.40+1.1%$12.56+33.6%+41.9%$465.62M$228.38M7.071,186News CoverageSLDBSolid Biosciences3.0047 of 5 stars$6.01+0.8%$15.00+149.6%-7.0%$464.10M$8.09M-2.15100ALMSAlumis3.4337 of 5 stars$4.61+3.8%$20.17+337.5%-59.6%$462.05MN/A0.00N/APositive NewsGap DownDRUGBright Minds Biosciences3.2134 of 5 stars$64.97+2.7%$81.00+24.7%+191.0%$445.81MN/A-69.86N/APositive NewsLXEOLexeo Therapeutics3.0458 of 5 stars$8.20-0.5%$17.00+107.3%+5.3%$444.97M$650K-2.5258Trending NewsAnalyst ForecastInsider TradeGap UpRAPTRapt Therapeutics3.159 of 5 stars$26.35-1.6%$24.78-6.0%+117.0%$443.05M$1.53M-1.8680Analyst RevisionGap DownAUTLAutolus Therapeutics3.4134 of 5 stars$1.65-0.6%$9.12+452.7%-65.5%$441.80M$10.12M-1.96330 Related Companies and Tools Related Companies FULC Alternatives INBX Alternatives ATXS Alternatives CYRX Alternatives SLDB Alternatives ALMS Alternatives DRUG Alternatives LXEO Alternatives RAPT Alternatives AUTL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTGN) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersHoly ****... This could actually MAGAA new document circulating from Washington is stirring major controversy — one that some say could redefine Am...StocksToTrade | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredNvidia CEO’s Regret: ‘I Wish I Gave [Elon] More’…Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VistaGen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VistaGen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
